1200 Pharma has filed a notice of an exempt offering of securities to raise $2,325,500.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, 1200 Pharma is raising up to $2,325,500.00 in new funding. Sources indicate that as part of senior management Director, Mark Attanasio played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.
About 1200 Pharma
1200 Pharma was launched in 2017 by a team of world-renowned chemistry and translational oncology researchers from Caltech and UCLA. We leverage breakthrough medicinal chemistry technology, cutting edge computational design, and data-driven biological research to accelerate drug discovery and deliver the right medicines to the right patients.
To learn more about 1200 Pharma, visit http://1200pharma.com/
Contact:
Mark Attanasio, Director
626-548-8304
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.